Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

The rise of GLP-1 drugs is a reminder that we must move beyond the equation of thinness as health and value. These drugs are not the answer to the deep-rooted cultural problem of fatphobia ...

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle ...